← Back to Search

Brain Stimulation

Repetitive Transcranial Magnetic Stimulation (rTMS) for Schizophrenia

N/A
Waitlist Available
Led By Michael Avissar, MD, PhD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks.
Awards & highlights

Study Summary

This trial will use magnetic pulses to try and lessen symptoms of schizophrenia, specifically auditory hallucinations.

Eligible Conditions
  • Schizophrenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total number of rTMS sessions completed
Total number of treatment emergent adverse events
Secondary outcome measures
Change in Auditory Hallucination Rating Scale (AHRS)
Change in Cardiff Anomalous Perceptions Scale (CAPS)
Change in Clinical Global Impression Improvement (CGI-I) Scale
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Individualized magnetic resonance imaging (MRI) guided rTMSExperimental Treatment1 Intervention
Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive a 20-min once-daily rTMS sessions over a period of 2 weeks (weekends off), and therefore accrue a total of 10 rTMS stimulation sessions. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Repetitive Transcranial Magnetic Stimulation (rTMS)
2019
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,431 Previous Clinical Trials
2,460,822 Total Patients Enrolled
24 Trials studying Schizophrenia
3,444 Patients Enrolled for Schizophrenia
Michael Avissar, MD, PhDPrincipal InvestigatorNew York State Psychiatric Institute
1 Previous Clinical Trials
3 Total Patients Enrolled
1 Trials studying Schizophrenia
3 Patients Enrolled for Schizophrenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are actively engaged in this research endeavor?

"Confirmed. According to the information available on clinicaltrials.gov, this medical experiment is actively enrolling participants since its initial posting on August 1st 2022 and last update of August 2nd 2022. A total of 12 patients are needed from a single location."

Answered by AI

Does the recruitment for this research include individuals older than twenty?

"According to the specified inclusion criteria, only individuals aged between 22 and 55 can join this clinical trial. Those younger than 18 are limited to 47 studies while there is a greater assortment of options for those over 65 with 169 available."

Answered by AI

Are there open slots to take part in the clinical research presently?

"Affirmative, the information found on clinicaltrials.gov shows that this study is currently recruiting participants. The trial was initially posted on August 1st 2022 and last updated a single day later, with 12 patients sought from one site."

Answered by AI

What objectives is the research team looking to accomplish with this clinical trial?

"The principle objective of this experimental trial, to be assessed over a two-week period, is the total number of treatment emergent adverse events. Secondary objectives include gauging changes in Cardiff Anomalous Perceptions Scale (CAPS), Psychotic Symptom Rating Scale (PSYRATS) and Scale for the Assessment of Positive Symptoms (SAPS). CAPS scores range from 0-32 with higher numbers indicating more perceptual anomalies; PSYRATS consists of 17 items rated from none to severe on auditory hallucinations and delusions; SAPS includes 34 items that measure positive symptoms related to schizophrenia each given an intensity score between 0-5."

Answered by AI

What are the ideal characteristics of a participant for this research effort?

"Candidates aged 22 to 55 with a schizophrenia diagnosis are eligible for this clinical trial. A ceiling of 12 participants exists for the experiment."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
New York State Psychiatric Institute
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
Michael Avissar 2022. "Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05319080.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top